We are international
Donate
• treatment options TEXT SIZE   
supportive care

Statement on the passing of Senator Kennedy
Yesterday morning the nation awoke to the news that Senator Edward M. "Ted" Kennedy passed away following a year-long battle with brain cancer. As an organization dedicated to improving the lives of people throughout the world who are touched by multiple myeloma, the IMF is particularly saddened by Sen. Kennedy’s death.
08.27.09





Yesterday morning the nation awoke to the news that Senator Edward M. "Ted" Kennedy passed away following a year-long battle with brain cancer. As an organization dedicated to improving the lives of people throughout the world who are touched by multiple myeloma, the IMF is particularly saddened by Sen. Kennedy’s death.

For the past half century, there has been no greater champion for the cause of improving healthcare for all Americans than Sen. Kennedy. One of his last legislative acts was to introduce, along with Sen. Kay Bailey Hutchison of Texas, the 21st Century ALERT Act to update the 1971 National Cancer Act.

In his statement introducing the bill (http://kennedy.senate.gov/newsroom/press_release.cfm?id=619520a7-5556-4c3e-ab40-1a2dcb07e989), Sen. Kennedy stated that "cancer today is no longer the automatic death sentence that it was when the war [on cancer] began." He understood, as few do, that a comprehensive approach including research, clinical trials, healthy living initiatives, public and medical education, and issues of survivorship—including mental health and social support—are all essential to address the needs of the more than 1.4 million Americans who are diagnosed annually with cancer. The 21st Century ALERT Act is both a timely and eloquent recognition that "we must move from a magic bullet approach to a broad mosaic of care..." This is something that we in the myeloma community understand and passionately support.

We hope that his vision and dedication to championing healthcare reform will inspire policy makers and citizens alike to take up the torch and finish the job. And as members of myeloma and cancer communities, we hope that the realization of the 21st Century ALERT Act will become one of his greatest legacies.

On behalf of the myeloma community, we extend our condolences to the Kennedy family. We share their grief and celebrate the life of a great American.

Susie Novis
President
Brian G.M. Durie, M.D.
Chairman, Board of Directors


 related videos
 related articles
A Patient Advocacy C...
Advocacy Staff
Advocacy Update - Au...
Advocacy Update - Au...
Advocacy Update - Fe...
Advocacy Update - Ju...
Advocacy Update - Ju...
Advocacy Update - Ju...
Advocacy Update - Ma...
Advocacy Update - Se...
Advocacy Update - Se...
Advocacy Update - Se...
Advocacy UpdateAugus...
IMF supports legisla...
Issues of importance...
Myeloma Advocacy Upd...
Myeloma Advocacy Upd...
New! Survey of your ...
President Unveils He...
Research
The Importance of Vo...
The International My...
The Power of Advocac...
Virginia Support Gro...

A Practical Guide to...
ASCO 2010: A phase I...
ASCO 2010: Bone mark...
ASCO 2010: Elotuzuma...
ASCO 2010: Lenalidom...
ASCO 2010: Mechanism...
ASCO 2010: Modified ...
ASCO 2010: Multiple ...
ASCO 2010: Neurotoxi...
ASCO 2010: Phase I s...
ASCO 2010: Phase Ib ...
ASCO 2010: Results o...
ASCO 2010: Stromal e...
ASCO 2010: Total the...
Clinically relevant ...
Common Symptoms Of M...
Confirmation of the ...
Developing a SNP Cla...
Eliminating the comp...
ESAs not the culprit...
Genetic association ...
Genetic Associations...
Genetic Associations...
Genetic polymorphism...
Genetic Variations A...
Genomic variation in...
IMWG consensus state...
IMWG Criteria for th...
IMWG Guidelines for ...
IMWG Guidelines for ...
IMWG Guidelines for ...
IMWG Guidelines for ...
International Myelom...
International Myelom...
Long-Term Follow-Up ...
Long-Term Follow-Up ...
New Approaches to Tr...
Oncology Nurses Take...
Osteonecrosis of the...
RT-PCR Amplicons in ...
Survival and Years o...
Use of Bisphosphonat...

What is multiple myeloma?
Dr. Morie Gertz of the Mayo Clinic in Rochester, MN.
ASCO 2010: A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
ASCO 2010: Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Lenalidomide maintenance after transplantation for myeloma.
ASCO 2010: Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.
ASCO 2010: Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial.
ASCO 2010: Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications.
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).
ASCO 2010: Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT) for myeloma.
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
A Patient Advocacy Coalition Led by the International Myeloma Foundation and the MDS Foundation Says Its Cancer Patient Statement of Principles Gains Momentum Going into the ASH Cancer Conference
Advocacy Staff
Advocacy Update - August 17, 2010
Advocacy Update - August 31, 2010
Advocacy Update - February 15, 2010
Advocacy Update - July 15, 2010
Advocacy Update - June 21, 2010
Advocacy Update - June 30, 2010
Advocacy Update - May 31, 2010
Advocacy Update - September 1, 2009
Advocacy Update - September 15, 2009
Advocacy Update - September 30, 2010
Advocacy Update
August 5, 2010
IMF supports legislation to require equitable insurance reimbursement for oral cancer drugs
Issues of importance to patients are getting lost in partisan battles in Congress. Get involved!
Myeloma Advocacy Update - January 31, 2010
Myeloma Advocacy Update - March 30, 2010
New! Survey of your experience in obtaining access to the cancer medications recommended by your physician.
President Unveils Health Reform Proposal
Research
The Importance of Voting on November 2nd
The International Myeloma Foundation, Marking 20 Years of Serving the Myeloma Community, Applauds, Members of the International Myeloma Working Group for Their Body of Work Being Presented at the ASH Hematology Conference
The Power of Advocacy
Virginia Support Group Leader Takes on Capitol Hill
WHAT IS MULTIPLE MYELOMA
A Practical Guide to Achieving and Maintaining the Best Response to Lenalidomide in Multiple Myeloma: Roundtable Proceedings
ASCO 2010: A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
ASCO 2010: Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Lenalidomide maintenance after transplantation for myeloma.
ASCO 2010: Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.
ASCO 2010: Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial.
ASCO 2010: Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications.
ASCO 2010: Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI).
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).
ASCO 2010: Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT) for myeloma.
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
Clinically relevant end points and new drug approvals for myeloma
Common Symptoms Of Multiple Myeloma
Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
Eliminating the complete response penalty from myeloma response criteria
ESAs not the culprit: More studies required
Genetic association with thalidomide mediated venous thrombotic events in myeloma indentified using targeted genotyping
Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma
Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma
Genetic polymorphisms of EPHX1, Gsk3 beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma
Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival
IMWG consensus statement on the role of vertebral augmentation in multiple myeloma
IMWG Criteria for the Diagnosis of Myeloma and Guidelines for the Diagnostic Work-Up of Myeloma
IMWG Guidelines for Facilities and Services for the Management of Myeloma Patients
IMWG Guidelines for the Management of Multiple Myeloma Patients Ineligible for Standard High-Dose Chemotherapy with Autologous Stem Cell Transplantation
IMWG Guidelines for the Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma
IMWG Guidelines for the Use of Bisphosphonates in Myeloma
International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma
International Myeloma Working Group Guidelines on Imaging Techniques in the Diagnosis and Monitoring of Multiple Myeloma1
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
New Approaches to Treatment for Multiple Myeloma: Durable Remission and Quality of Life as Primary Goals
Oncology Nurses Take the Lead in Providing Novel Therapy Guidelines for Multiple Myeloma
Osteonecrosis of the Jaw and Biphosphonates
RT-PCR Amplicons in the Plasma of Multiple Myeloma Patients
Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma
Use of Bisphosphonates in Multiple Myeloma: IMGW Response to Mayo Clinic Consensus Statement